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E26 transformation-speciﬁc sequence (ETS)-2 is a transcriptional
modulator located onchromosome 21, alterations in its expression
have been implicated with a reduced incidence of solid tumors in
Down syndrome patients. MicroRNAs (miRNAs) are thought to
participate in diverse biological functions; however, the regula-
tion of miRNAs is not well characterized. Recently, we reported
that miR-196b is highly expressed in gastric cancers. Herein, we
demonstrate thatmiR-196b expressionwassigniﬁcantly repressed
by ETS2 during gastric cancer oncogenesis. We demonstrate that
knockdown of endogenous ETS2 expression increases miR-196b
expression. A genomic region between 2751 and 2824 bp up-
stream of the miR-196b transcriptional start site was found to
be critical for the repression activity. This putative regulatory
promoter region contains three potential ETS2-binding motifs.
Mutations within the ETS2 binding sites blocked the repression
activity of ETS2. Furthermore, knockdown of ETS2 or overex-
pression of miR-196b signiﬁcantly induced migration and inva-
sion in gastric cancer cells. In addition, alterations in ETS2 and
miR-196b expression in gastric cancer cell lines affected the ex-
pression of epithelial–mesenchymal transition-related genes. The
levels of vimentin, matrix metalloproteinase (MMP)-2 and MMP9
were drastically induced, but levels of E-cadherin were decreased
in shETS2- or miR-196b-transfected cells. Our data indicate that
ETS2 plays a key role in controlling the expression of miR-196b,
and miR-196b may mediate the tumor suppressor effects of ETS2.
We demonstrated that miR-196b was transcriptionally regulated
by ETS2 and there was an inverse expression proﬁle between
miR-196b and ETS2 in clinical samples. This ﬁnding could be
beneﬁcial for the development of effective cancer diagnostic and
alternative therapeutic strategies.
Introduction
Gastric cancer is a common cancer type and especially prevalent in
the Andean region of South America and in the far east (1) and is the
second leading cause of cancer-related deaths in the world (2). The
development and progression of gastric cancer have been character-
ized by multiple genetic mutations and the dysregulation of both
coding and non-coding genes including microRNAs (miRNAs) (3,4).
miRNAs are endogenous non-coding short RNAs of 21–23 nucleo-
tides in length. MiRNAs were initially discovered in Caenorhabditis
elegans and thousands have since been identiﬁed in many organisms,
including humans, mammals, invertebrates, insects, plants and viruses
(5). In humans, miRNAs play important roles in cellular physiology,
development and disease by negatively regulating gene expression
through translational repression or post-transcriptional degradation
(6,7). MiRNAs regulate their target genes through the 3#untranslated
region of the gene. Depending on the target gene, miRNAs act as
tumor suppressor genes or have an oncogenic role in cancer forma-
tion. Tumor-suppressive miRNAs usually repress growth-promoting
genes, and oncogenic miRNAs often target growth-stimulatory genes.
The miR-196s family of miRNAs is encoded at three paralogous
loci in the mammalian HOX clusters and several HOX genes are
regulated by miR-196s (8,9). The miR-196 family has been shown
to be critical transcriptional regulators involved in embryo develop-
ment (10–13), diseases (14–16) and tumorigenesis (17–20). Dysregu-
lation of miR-196b has been reported in a variety of human cancers,
such as colorectal cancer (21), leukemia (22–26), glioblastoma (27)
and breast cancer (28), suggesting that miR-196b may be important in
multiple tumor types. Our previous study also demonstrated that ab-
normal DNA hypomethylation induces the overexpression of miR-
196b in human gastric cancers (29).
There is a signiﬁcant amount of information on aberrantly expressed
miRNAs and their tumorigenic effects in human cancers, but the de-
tailed transcriptional regulations of these miRNAs remain poorly un-
derstood. Recent studies have suggested possible mechanisms,
including epigenetic alterations and deregulated transcription pro-
cesses. Most miRNAs are transcribed by RNA polymerase II. There-
fore, similar to most protein-coding genes, the up or downregulation of
miRNAs can be further controlled by transcription factors targeting
their promoters. The mixed lineage leukemia gene directly upregulates
miR-196b transcription in leukemia (22). Velu et al. (16) found that
miR-196b is directly regulated by the transcription factor zinc ﬁnger
protein growth factor independent-1 during myelopoiesis. In this study,
we found that E26 transformation-speciﬁc sequence (ETS)-2 can reg-
ulate miR-196b expression in gastric cancers, and there is an inverse
expression between ETS2 and miR-196b in clinical samples.
ETS2 is a member of a highly conserved transcription factor ETS
family known to have a characteristic winged helix-turn-helix DNA-
binding domain that interacts with a core GGAA/T consensus se-
quence found within promoter regions of target genes (30–32).
ETS2 has been shown to play important roles in embryo development
(33–35), senescence (36), vasculogenesis (34), immunity (37), osteo-
genesis (38) and tumorigenesis. The gene that encodes ETS2 is lo-
cated on human chromosome 21q22.3 and has been reported to be
overexpressed in the brain and ﬁbroblasts of subjects with Down
syndrome (DS) (39,40). Sussan et al. (41) demonstrated that enhanced
ETS2 activity in a DS animal model induced signiﬁcant inhibition of
intestinal tumors formation. Therefore, ETS2 could have a tumor
suppressor role. Whether the deregulated expression of ETS2 leads
to a similar oncogenic activity in human gastric cancers is not known.
In this study, we report that loss of ETS2 expression and increased
miR-196b levels are observed in gastric cancer samples. We applied
a bioinformatics approach to investigate the ETS2-binding potential
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ETS, E26 transformation-speciﬁc sequence; miRNA, microRNA; mRNA,
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experiments using real-time quantitative PCR (RT–qPCR), a chroma-
tin immunoprecipitation (ChIP) assay and a promoter reporter assay
to demonstrate that downregulation of ETS2 could directly regulate
miR-196b expression and affect migration and invasion activity in
gastric cancer cells.
Materials and methods
Cell lines and human gastric tissues
The human gastric cancer cell lines, AGS, HR and the embryonic kidney cell,
293Twere cultured as described previously (29). Paired samples of tumor and
adjacent normal gastric tissues (63 pairs) were obtained from patients who had
undergone curative gastric resection for primary gastric cancer at Taipei Vet-
erans General Hospital, Taiwan. The study was approved by the Institutional
Review Board, and informed consent was provided by all patients. Immedi-
ately after surgical resection, tissues were snap-frozen in liquid nitrogen and
stored at  80C until use.
Analysis of gene expression
Gene expression of ETS2 and epithelial–mesenchymal transition (EMT)-related
genes in cell lines and tissues were detected with RT–qPCR using the SYBR
GreenIprotocol(Bio-Rad,Hercules,CA).ExpressionanalysisofmiR-196bwas
performedbya quantitativestem-loop PCR,withU6RNAasaninternalcontrol.
All values were normalized against glyceraldehyde 3-phosphate dehydrogenase
messenger RNA (mRNA) or U6 RNA. The primer sequences are listed in
Supplementary Table 1, available at Carcinogenesis Online.
Plasmid constructs
The full-length human ETS2 (NM_005239) gene was subcloned into the
pIRES-hrGFP-1a vector (Clontech, Mountain View, CA) and designated as
Flag-ETS2. Luciferase reporter constructs containing the promoter regions
of pre-miR-196b (nucleotides þ36 to  996 with the ETS2 binding site
GGA A/Tat position  851 to  683 bp and  533 to  159 bp) were subcloned
into the pGL3-basic vector (Promega, Madison, WI) and designated as differ-
ent truncated wild-type pGL3-pre-miR-196b promoters: FL, N, C and P. ETS2
core-binding site mutations (GGA A/T) within the promoter regions of pre-
miR-196b were generated using the QuickChange Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA). The pre-miR-196b promoter has three ETS2
binding sites at the core binding site ( 851 to  683 bp) and the GGA A/T of
thecore bindingsitewasmutatedat the 824 to 821 site(M1),at the 767 to
 764 sites (M2) or at the  755 to  752 sites (M3). The RT–qPCR primers
usedin the reporterandmutagenesisassayarelisted in SupplementaryTables2
and 3, available at Carcinogenesis Online.
A partial human pri-miR-196b gene (a 270 bp complementary DNA frag-
ment encompassing 27 209 270 bp to 27 209 001 bp of chromosome 7) was
subcloned into the lentiviral expressionvector, pLKO.1-shLuc (National RNAi
Core Facility, Academia Sinica, Taiwan) in place of shLuc and renamed
pLKO.1-196b. The pLKO.1-196b was used to induce expression of miR-
196b in cells.
RNA interference with shRNA and ectopic expression of miR-196b
Stable AGS cells were plated and infected with lentiviruses expressing
shETS2, miR-196b or shLuciferase (shLuc) in the presence of 8 lg/ml poly-
brene for 24 h followed by puromycin selection (2 lg/ml; 48 h). RT–qPCR
and/or western blotting were performed to validate the knockdown and the
expression of mature miR-196b. The shRNA and miRNA constructs are de-
scribed in the Supplementary Materials and Methods section, available at
Carcinogenesis Online.
Antagomirs assays
The sequence complementary to miR-196b 5#-CCCAACAACAGGAAA-
CUACCUA-3# and the control sequence, 5#-GUGUAACACGUCUAUACGCC-
CA-3# were synthesized with 2#-OMe modiﬁed bases, phosphothioate on the
ﬁrst two and last four bases, and a three cholesterol modiﬁcation through a hy-
droxyprolinol linkage (Dharmacon, Lafayette, CO). The cells were incubated
with 100 nM antagomir for 1 day to suppress miR-196b expression.
Antibodies, immunoblotting, immunostaining and staining for F-actin
Immunoblotting was performed as described previously (42). Protein lysates
(30 lg) were electrophoresed on 10% sodium dodecyl sulfate polyacrylamide
gels and transferred onto polyvinylidene diﬂuoride membranes (Millipore,
Bedford, MA). The membranes were incubated with primary antibodies over-
night at 4C and then with the appropriate horseradish peroxidase-conjugated
secondary antibody (Amersham Biosciences, Piscataway, NJ).
The primary antibodies against Flag or actin were purchased from Sigma
(St Louis, MO), and the antibody against ETS2 was obtained from Santa Cruz
(Santa Cruz, CA). Protein signals were detected by an enhanced chemilumi-
nescence kit (PerkinElmer, Waltham, MA). The levels of protein expression
were normalized against actin.
Immunostaining was performed as described previously (42). The incuba-
tion with rhodamine–phalloidin (1 U/ml; Invitrogen, Carlsbad, CA) was
performed at room temperature for 15 min followed by counterstaining with
4#,6-diamidino-2-phenylindole. The ﬂuorescent images were captured using
a Bio-Rad Radance 2100 confocal microscope ( 60 oil immersion lens).
Cell migration/invasion assay
The cells were examined for migration and invasion abilities invitro in a trans-
well assay The lower side or the upper side of polycarbonate membranes (8 lm
pores) of a transwell (Costar, Lowell, MA) were coated with type I collagen
(50 lg/ml) or Matrigel (80 lg/well) for the migration and invasion assays,
respectively. The cells were added to the upper chamber of a transwell; after
incubation for 16 h at 37C, the cells on the lower side were stained with
Giemsa stain. The level of migration or invasion was determined using a mi-
croscope at  200 magniﬁcation. All experiments were repeated in triplicate.
Chromatin immunoprecipitation reactions
The ChIP assays were performed as described previously (42). The cells were
ﬁxed with 1% formaldehyde, harvested and lysed in sodium dodecyl sulfate
buffer containing 50 mM Tris–HCl (pH 8.1), 0.5% sodium dodecyl sulfate,
100 mM NaCl, 5 mM ethylenediaminetetraacetic acid and protease inhibitors.
The pellet was sonicated using 1 s pulses separated by 5 s for 4 min at output
level 6 using a Sonicator XL2020 (Misonix, Farmingdale, NY). The sheared
chromatin was precleared with protein A beads (30 ll; Amersham Bioscien-
ces), followed by incubation with 5 lg of anti-Flag mAb, anti-ETS2 or mouse
IgG Ab (PerkinElmer). Untreated sonicated chromatin was used as input.
Puriﬁed DNA was subjected to PCR reactions using the primers described in
Supplementary Table 4, available at Carcinogenesis Online.
Promoter reporter assay
HEK293T cells (5   104 cells per well) were seeded in 24-well plate and
cotransfected with 0.25 lg of either control vector or Flag-ETS2 construct
in conjunction with 0.25lg of either pLuc-FL (wild-type or mutant),thevaried
truncated forms and 0.05 lg of pRL-TK (Promega) using TurboFect reagent
(Fermentas, MD). After 48 h, luciferase activity was measured using the Dual-
Glo Luciferase assay System Kit (Promega).
Statistical analysis
All data are expressed as the mean ± SD; groups were compared using Stu-
dent’s t-test. Categorical variables were compared using the Wilcoxon rank
test. A P value ,0.05 was considered statistically signiﬁcant.
Results
Prediction of potential ETS2 binding sites in the miR-196b promoter
In previous studies, we investigated the expression and epigenetic
regulation of miRNAs in human gastric cancers (29,43,44), including
miR-196b, which has been implicated in many human cancers. There-
fore, we investigated about the speciﬁc transcription control of this
important miRNA gene in human cancer cells.
Inpreliminaryexaminations,bioinformatictools(suchastheTRAN-
FAC public database) were utilized to interrogate the putative promoter
region of miR-196b. Several transcription factor binding sites were
implicated in the miR-196b promoter region, including ETS2. A con-
sensus ETS2-binding motif, GGA A/T (30–32), was used to scan the
upstream promoter region of miR-196b. In silico analyses revealed that
six ETS2-binding motifs were located within upstream 1 kb region
from the transcription start site of miR-196b, three (between  824
and  752) were located in the conserved non-coding block (CNB)
and three additional motifs (between  399 and  205) were in non-
conserved regions (Figure 1). It is known that the binding motifs of the
evolutionarily conserved transcription factors tend to reside in CNBs
within the promoter regions of their putative target genes (28,45).
Validation of the predicted ETS2-binding motifs using ChIP assays
ChIP and reporter assays were performed to discover whether these
motifs are functional binding sites for ETS2. ChIP is a powerful tech-
nique for analyzing transcription factor binding sites in living cells.
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with a Flag-ETS2 fusion protein construct using anti-ETS2 and mono-
clonal anti-Flag antibodies. In parallel, control ChIP assays experi-
ments were performed using an anti-IgG antibody.
Brieﬂy, we used formaldehyde to cross-link transcription factors to
chromatin. The chromatin was sheared into small fragments and anti-
bodies against Flag-ETS2 or control IgG were used to immunopre-
cipitate the nucleoprotein complexes. The DNA fragments were
analyzed by PCR for three regions, including the three ETS2 binding
sites in the CNBs (miR-196b-1: between  851 and  683 bp), the
three ETS2 binding sites in the non-conserved regions (miR-196b-2:
between  533 and  159 bp) and the lack of ETS2 binding sites in the
nearby promoter region (miR-196b-3: between  154 and  3 bp).
There are two target genes of ETS2 that have been previously
empirically veriﬁed, DUSP6 and AURKA, which were used as our
positive controls (46,47). As shown in Figure 2A, only the primers of
miR-196b-1 produced strong PCR products, which suggested that
ETS2 protein formed complexes with the predicted motifs between
 851 and  683 bp of the miR-196b promoter. In addition, we have
performed additional ChIP assays using the parental AGS cells and
quantitative PCR to measure endogenous ETS2 binding to the miR-
196b promoter region. As shown in Supplementary Figure 1, available
at Carcinogenesis Online, the data were similar to the result in
Figure 2A using the Flag-tagged ETS2 fusion protein. Only the miR-
196b-1 region had the strong binding afﬁnity. This result demonstrates
that ETS2 protein speciﬁcally interacts with the miR-196b promoter
region.
Deletion analysis highlights a critical  996 to  610 bp fragment in
the miR-196b promoter region
To evaluate if the negative regulation of miR-196b by ETS2 was
a direct transcriptional modulation, we subcloned a  996 to þ36
bp fragment of the promoter region of miR-196b into the luciferase
expression pGL3-basic plasmid (Figure 2B). This construct was des-
ignated as FL construct and included the predicted ETS2 recognition
sites. It was then transfected into 293T cells for a reporter assay. The
expression levels of the FL construct were signiﬁcantly increased
compared with the pGL3-basic construct. These data indicated that
the 1 kb upstream region of miR-196b gene contained a strong pro-
moter region. Subsequently, when the FL reporter construct was co-
transfected with an ETS2 expressionvector into 293T cells, it induced
a .40% reduction in luciferase activity compared with the mock
control without ETS2 overexpression (Figure 2B).
To determine which portion of the miR-196b promoter region
might be critical for the observed transcriptional regulation by
ETS2, we created different truncated forms of the miR-196b promoter
for ETS2 reporter assay experiments. These truncated form constructs
included: N:  996 to  610 bp,; C:  610 to  2 6 0b pa n dP : 260 to
þ36 bp. These constructs are designated from the miR-196b transcrip-
tional start sites. The promoter structures and expression patterns are
shown in Figure 2B. The N-fragment construct contains three ETS2-
binding motifs in the evolutionarily CNB region and minimal expres-
sion of luciferase was conferred by the N-fragment construct which
could be due to endogenous ETS2 activity. Intriguingly, the largest
alteration in luciferase expression occurred when the region from
 996 to  610 was deleted (the C construct). The P fragment did not
affect expression activity compared with the control vector (Figure 2B).
These data suggest that there is a critical region between  996 and
 610 bp thatis necessary for transrepression of the promoter constructs.
We next tested the ability of the exogenous ETS2 transcription
factor to repress the miR-196b promoter. We cotransfected different
miR-196b reporter constructs along with the ETS2 expression vector
or an empty control vector into 293T cells. Overexpression of ETS2
led to a  50% decrease in the transactivation of the FL and N con-
structs, but the C and P constructs were not affected by ETS2 expres-
sion (Figure 2B, solid bars). Taken together with the ChIP data, these
Fig. 1. ETS2 binding sites in miR-196b promoters. Human and mouse promoter regions of miR-196b contain six putative binding sites for ETS2 (GGA A/T),
three of them located in a human–mouse conserved region (between  824 and  752). H, human; M, mouse.
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(N:  996 to  610) are critical for the direct ETS2 repression of miR-
196b promoter activity.
To clarify which ETS2 binding sites motifs are involved in the re-
pression of miR-196b promoter activity, we generated an additional
series of mutant constructs within the core binding site motif of ETS2.
These constructs were as follows: M1 ( 824 to  821,
GGAT/AACG), M2 ( 767 to  764, GGAA/AAGG) and M3
( 755 to  752, GGAT/AACG). In the presence of exogenous
ETS2, the promoter activity of the wild-type FL construct was repressed
by 50%, but mutations of the three ETS2-binding motifs resulted in
signiﬁcant enhancement in luciferase activity (1.5- to 3-fold;
Figure 2C). These data imply that all three ETS2-binding motifs are
involved in the repression of the miR-196b promoter region by ETS2.
In summary, these results indicate that ETS2 can directly repress
miR-196b transcription activation through the three ETS2-binding
motifs. This repression was strong within the CNB region. This ﬁnd-
ing provides evidence that miR-196b is indeed a target gene of ETS2.
An inverse correlation between ETS2 mRNA and miR-196b expression
levels in gastric cancer tissues
Previously, we showed that miR-196b is overexpressed in gastric
cancers. Here, we investigated the expression of ETS2 and miR-
196b in gastric cancers by RT–qPCR. Expression levels of ETS2
and miR-196b were analyzed in paired adjacent normal and gastric
tumor tissues from 63 patients (Figure 3). An inverse correlation was
observed between ETS2 mRNA and miR-196b level in the tumor
specimens. ETS2 mRNA levels were signiﬁcantly suppressed in the
gastric tumors compared with the adjacent normal tissue (Figure 3,
left panel, P , 0.001). In contrast, expression of miR-196b was re-
markably higher in the tumor tissues (Figure 3, right panel, P ,
0.001). Therefore, it is possible that in the course of gastric cancer
progression, ETS2 was downregulated and miR-196b was subse-
quently upregulated.
ETS2 regulates miR-196b expression in gastric cancer cell lines
To determine the relevance of ETS2-miR-196b transcriptional regu-
lation, the expression proﬁles of ETS2 and miR-196b were investi-
gated in two gastric cancer cell lines by RT–qPCR. AGS and HR are
the primary and metastatic gastric cancer cell lines, respectively
(48,49). Primary gastric cancer cells (such as AGS) highly express
ETS2, but metastatic gastric cancer cells (such as HR) poorly express
ETS2 (Figure 4A). In contrast, AGS cells failed to show detectable
levels of miR-196b, but HR cells do have high expression levels of
miR-196b (Figure 4A). These data implied that ETS2 is a potential
repressor of miR-196b and the dysregulation of ETS2 may be in-
volved in gastric cancer progression.
To explore the ability of ETS2 to alter the expression of endoge-
nous miR-196b in gastric cancer cells, the ETS2 shRNA vector was
used toknockdown endogenous ETS2expressioninAGS cells. Trans-
duction of shETS2 reduced ETS2 expression at both mRNA and pro-
tein levels in AGS cells (Figure 4B). In addition, we transfected HR
cells with an ETS2 expression plasmid and found an increased ex-
pression of ETS2 mRNA and protein in HR cells (Figure 4C).
Fig. 2. ETS2 directly regulates the expression of miR-196b. (A) ChIP assays
with anti-Flag and anti-ETS2 antibodies showed binding of Flag-ETS2 to the
promoters of miR-196b in AGS cells transfected with Flag-ETS2. Dual
speciﬁcity phosphatase 6 (DUSP6) and aurora kinase A (AURKA) are
conﬁrmed ETS2 targets genes (46,47) and used as positive controls. The
regions ampliﬁed by ChIP are: miR-196b-1:  851 to  683, miR-196b-2:
 533 to  159 and miR-3:  154 to  3. I, input DNA; a-F,
immunoprecipitation with anti-Flag antibody from cells expressing Flag-
ETS2; a-E, immunoprecipitation with anti-ETS2 antibody from cells
expressing Flag-ETS2; a-mIgG, immunoprecipitation with mouse IgG
antibody was used as a negative control. (B) The promoter of miR-196b was
repressed by ETS2. 293T cells were transiently cotransfected with Flag-
ETS2 or mock vector and the wild-type miR-196b promoter (FL) or the
various truncatedmiR-196bpromoterconstructs:N,C andP. Thesepromoter
sequences included in each were indicated by the numbers at the 5# and 3#
termini. Normalized luciferase activity from triplicate samples is presented
relative to that of cells transfected with the pGL3-basic construct. (C) The
mutation of ETS2-binding motifs induced the promoter activities of miR-196b.
293T cells were transiently cotransfected with Flag-ETS2 or mock vector and
wild-type miR-196b promoter (FL) or miR-196b promoter ETS2 binding site
mutants (M1, M2 and M3). The miR-196b promoter constructs with the
mutated core binding sequences were designated as M1, M2 or M3.
Normalized luciferase activity from triplicate samples is presented relative to
that of cells transfected with the FL construct. Luciferase activity was
measured 48 h after transfection. The transfection efﬁciency was normalized
against pRL-TK activity. The experiment was repeated twice with similar
results.  P , 0.05,   P , 0.01.
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we analyzed the expression levels of miR-196b in AGS–shETS2 and
HR–ETS2 cells (Figure 4D). The expression levels of the miR-196b
gene were increased in the ETS2-knockdown AGS cells. In contrast,
the expression levels of miR-196b were decreased in the ETS2-over-
expressed HR cells.
Fig. 3. Expressionproﬁles of ETS2 and miR-196bin gastric tumors. Examination of ETS2 mRNA and miR-196bexpression in 63 pairs of gastriccancer samples.
The results were normalized against the expression level of glyceraldehyde 3-phosphate dehydrogenase mRNA or U6 RNA in each sample, respectively. The box
plot shows the data distribution across the group classiﬁcation and presents the 75th and 25th percentile (upper and lower quartile) with the median value in
between. N indicates the average expression level of all 63 normal adjacent tissues; T indicates the average expression level of all 63 gastric tumor tissues. There
was a signiﬁcant difference between the level of ETS2 mRNA and miR-196b when tumors were compared with the adjacent tissue.
Fig. 4. Identiﬁcation of ETS2 repressed miR-196b expression in gastric cell lines. (A) Expression proﬁles of ETS2 and miR-196b in gastric cancer cell lines.
Expression levels of ETS2 mRNA and miR-196b in gastric cancer cell lines were detected using RT–qPCR by the SYBR Green I protocol. (B) Suppression of
ETS2 in AGS cells was achieved with shETS2 lentiviral infection. A control shLuc lentivirus was used as a negative control. The effect of ETS2 knockdown was
veriﬁed in the AGS–shETS2 cells by RT–qPCR and western blotting using an anti-ETS2 antibody. shETS2 knockdown reduced the level of endogenous ETS2
mRNA and protein by  60%. The expression of ETS2 and miR-196b were detected using RT–qPCR. shLuc was used as the negative control. (C) Overexpression
of ETS2 in HR cells was achieved with Flag-ETS2 plasmids transfection. Overexpression was veriﬁed in the HR–ETS2 cells by RT–qPCR and western blotting
using an anti-ETS2antibody. HR cells transfected with Flag-ETS2plasmids increased ETS2 expression in both mRNA and protein levels. Expression of ETS2 and
miR-196b were detected using RT–qPCR. Mock transfections were used as negative controls. (D) After shETS2 knockdown of endogenous ETS2, expression of
miR-196bin AGS cells was upregulated. After transfected with the Flag-ETS2 plasmid, the expression of miR-196bin HR cells was downregulated. In RT–qPCR,
all values of ETS2 or miR-196b were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA or U6 RNA, respectively. For western
blotting, total proteins (30 lg) were loaded and total actin was used as the internal control. The standard deviation is indicated.  P , 0.05,   P , 0.01.
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expression in gastric cancer cells.
Suppression of ETS2 or overexpression of miR-196b resulted in actin
organization and increased invasion in AGS primary gastric cancer
cells
Recently, miR-196b was found to be upregulated in human gastric
tumors (29) and was considered a member of a metastasis-related
miRNA family (28). However, the functional attributes of
miR-196b associated with gastric tumor progression have not been
experimentally demonstrated.
To explore the functional role of miR-196b in gastric cancers pro-
gression, ectopic expression of miR-196b was established using a len-
tiviral vector (lenti-196b; Figure 5A). Intriguingly, downregulation
of ETS2 (using shETS2) and ectopic expression of miR-196b (using
lenti-196b) signiﬁcantly induced distinct morphological changes in
the AGS primary gastric cancer cells; all AGS cells exhibited a trans-
formed ﬁbroblast-like cell arrangement (Figure 5B).
The polymerization and depolymerization of F-actin are essential
for cell motility. To assess whether the observed arrangements of the
actin cytoskeleton could affect the migration of shETS2- or lenti-
196b-treated AGS cells, we examined cellular actin structure with
phalloidine staining. The F-actin positive membrane protrusions were
signiﬁcantly increased in addition to the F-actin organization
enhancement in the shETS2- or lenti-196b-treated AGS cells
(Figure 5C).
We examined the effects of silencing ETS2 or overexpressing miR-
196b on cell migration and invasion. The knockdown of ETS2 dras-
tically increased the migration and invasion ability of AGS cells
(Figure 6). Furthermore, when miR-196b was overexpressed in
AGS cells, a signiﬁcant induction of cell migration and invasive ac-
tivity was observed (Figure 6). In contrast, in the metastatic gastric
cancer HR cells, overexpression of ETS2 or knockdown of miR-196b
repressed cell migration and invasion (Supplementary Figure 2 is
available at Carcinogenesis Online).
These results suggest that ETS2 affects cell migration partly via
regulation of its downstream target genes, such as miR-196b. ETS2
may serve as an upstream participant in this particular miRNA regu-
lation pathway for cytoskeleton migration.
Suppression of ETS2 expression and forced expression of miR-196b
resulted in differential expression of EMT-related genes
Due to the strong implication of this pathway in migration and in-
vasion, we then investigated the possible involvement of ETS2 and
miR-196b in the regulation of EMT-related genes. The process of
EMT is a particular cellular program that converts polarized immotile
epithelial cells into motile mesenchymal cells. During EMT, cells lose
epithelial features through repression of E-cadherin expression and
acquire mesenchymal characteristics such as increased vimentin ex-
pression. (50,51). The EMT processes enables cancer cells to increase
metastatic behavior and promote malignant phenotypes (52). To ex-
plore the functional roles of ETS2 and miR-196b in gastric cancer
metastasis, we investigated the expression proﬁles of EMT-related
genes (E-cadherin, vimentin, matrix metalloproteinase (MMP)-2
and MMP9) with real-time reverse transcription–PCR. E-cadherin,
a marker of the epithelial-type cells, was more highly expressed in
parental AGS cells than in parental HR cells (Figure 7A). In contrast,
the expression levels of vimentin, MMP2 and MMP9, markers for the
mesenchymal-type cells, were elevated in parental HR cells
(Figure 7A).
Fig. 5. Knockdown of ETS2 or overexpression of miR-196b affected the morphological changes and actin organization of AGS cells. (A) Knockdown of ETS2 and
overexpression of miR-196b in AGS cells were conﬁrmed by reverse transcription–PCR. (B) The morphology of AGS cells after downregulation of ETS2 by shRNA
oroverexpression ofmiR-196b. AlteredmorphologiesofAGScells were revealed by phase contrastmicroscopy. Imagesweretaken5–7daysafter infection.Original
magniﬁcation:  200. (C) Loss of actin organization in shETS2- and miR-196b-treated cells. Control shLuc-treated, shETS2- and miR-196b-treated AGS cells were
ﬁxed and stained with rhodamine–phalloidine and 4#,6-diamidino-2-phenylindole to detect F-actin and the nucleus, respectively. Bar, 20 lm.
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765We then examined the effects of ETS2 expression on the levels of
EMT-related gene. The levels of E-cadherin were drastically reduced
in shETS2-treated AGS cells; however, the expression levels of
vimentin, MMP2 and MMP9 were increased (Figure 7B, upper
panel). In contrast, when ETS2 was overexpressed in HR cells, a
signiﬁcant reduction of vimentin, MMP2 and MMP9 and an increase
in E-cadherin expression were observed (Figure 7B, lower panel).
Similar phenotypes were observed in miR-196b-treated cells. The
levels of E-cadherin were signiﬁcantly reduced in lenti-196b-treated
AGS cells. In contrast, vimentin, MMP2 and MMP9 were upregulated
(Figure 7C, upper panel). Antagomirs can efﬁciently and speciﬁcally
silence endogenous miRs (53). Therefore, when endogenous miR-
196b expression was suppressed by antagomir-196b in HR cells, the
levels of vimentin, MMP2 and MMP9 were drastically reduced and
E-cadherin was increased (Figure 7C, lower panel).
We further investigated whether the regulation of EMT-related genes
by ETS2 was partly mediated through miR-196b. In AGS cells, the
expression levels of miR-196b gene were increased by shETS2 treat-
ment (Figure 4D). When we used the antagomir-196b to inhibit miR-
196b expression in shETS2-treated AGS cells, the expression patterns
of E-cadherin, MMP2 and MMP9 were reversed (Figure 7D). This
supports our hypothesis and strongly suggests that a new ETS2-miR-
196b regulatory cascade is operating during gastric cancer progression.
To explore the relevant roles between ETS2-miR-196b and EMT-
related genes in clinical gastric cancer specimens, the expression
proﬁles of ETS2, miR-196b, E-cadherin, vimentin, MMP2 and
MMP9 in 59 gastric cancer sample pairs were further examined by
real-time reversetranscription–PCR (Supplementary Figure 3 is avail-
able at Carcinogenesis Online). In most gastric cancer specimens,
ETS2 and E-cadherin were downregulated. Expression of miR-196b
was upregulated as expected, but the expression of vimentin, MMP2
and MMP9 were not signiﬁcantly modulated in vivo. Unlike the
in vitro two-dimensional cultured cells, these EMT-related genes
might be modulated by many other signaling pathways in the tumor
microenvironment. Nonetheless, our data strongly demonstrated the
regulatory relationship between ETS2, miR-196b and E-cadherin in
clinical gastric cancer tissues.
Discussion
MiRNAs have been shown to be a signiﬁcant gene modulator during
gastric cancer progression; therefore, global miRNA expression pro-
ﬁles have been performed using microarray, real-time PCR or next-
generation sequencing approaches (3,4,54). There is a signiﬁcant
amount of information on aberrantly expressed miRNAs and their
tumorigenic effects in gastric cancers, but the detailed control mech-
anisms of such miRNA dysregulation remain poorly understood. This
is illustrated in our previous ﬁnding of a hypomethylated miR-196b
promoter in cells (29).
In our previous study, miR-196b was dramatically overexpressed in
gastric cancer tissue samples with a hypomethylated promoter. How-
ever, a hypomethylated miR-196b promoter was also observed in nor-
mal ﬁbroblast cells that still expressed miR-196b at low levels. We then
demonstrated that normal ﬁbroblast cells did not restore the expression
status of miR-196b following treatment with demethylation agents (29).
This implies that the expression of miR-196b requires additional tran-
scription regulatory factors. In this study, we demonstrated that ETS2
could be one of the key factors repressing the expression of miR-196b.
These combined data indicate that the regulation of the expression of
miR-196b required both cis elements (e.g. CpG island methylation) and
trans-factors (e.g. ETS2) in gastric cancers.
The overexpression of ETS2 has been reported in a variety of human
cancers (55–59), suggesting that ETS2 may be important in multiple
tumors as an oncogene or a tumor repressor. Previous studies have
revealed that certain tumor suppressor genes are regulated by ETS2.
For example, ETS2 acts as a transcriptional repressor by downregulat-
ing the tumor suppressor gene BRCA1 in breast cancer cells (45).
The discovery of ETS2 downstream target genes could expand our
knowledge regarding the ETS2 modulation of gastric cancer progres-
sion and would imply a range of novel ETS2 functions. Based on
ChIP and reporter assay data, we demonstrate that ETS2 directly
regulates miR-196b expression in gastric cancer cells. However, cu-
mulative evidence suggests that ETS protein is not working alone but
rather depends on requisite partners for target speciﬁcity and combi-
natorial control for gene regulation (60). In our study, ETS2 repressed
expression of miR-196b but induced expression of AURKA and
DUSP6. (46,47). A dichotomy of ETS2 transcriptional activity,
whereby it acts as both an activator and a suppressor, was reported
previously in various cell lines (60–62). Therefore, ETS2 has diverse
activities across various human cell types; these activities are likely to
be cell context-dependent involving different target genes (61,62).
DS patients present many clinical phenotypes including intellectual
disability and an apparent decreased risk of certain cancers including
gastrointestinal cancers (39,40,63). ETS2 is one of the key genes re-
siding in the DS critical region on chromosome 21. Previous DS
animal model studies demonstrated that ETS2 had a tumor suppres-
sion role in intestinal tumor oncogenesis (41). Our study is the ﬁrst to
report that ETS2 could serve as a transcriptional repressor to down-
regulate miR-196b expression for the inhibition of gastric cancer cell
mobility. In addition to miR-196b, ETS2 has been reported to regulate
the expression of miR-126 in endothelial cells and may mediate the
angiogenesis process (34). Many miRNAs are dysregulated in gastric
cancers (3,4,54). Whether ETS2 could modulate expression of other
cancer-associated miRNAs in gastric cancers is unknown, but the
implications of a novel transcription factor–miRNA regulatory
circuitry are signiﬁcant and deserve further elucidation.
Previous studies have demonstrated that ETS2 mediates cyclic aden-
osine 3#,5#-monophosphate-induced MMP2 expression activity during
embryo development (33). In our study, we demonstrated that ETS2
regulated MMP2 and other EMT-related genes partially through
miR-196b in vitro. We also observed a correlation between ETS2,
Fig. 6. Knockdown of ETS2 or overexpression of miR-196b resulted in
induction of migration and invasion. ETS2 knockdown and miR-196b
overexpression resulted in a 30–50% induction in migration (A) and invasion
(B) activity in AGS cells. AGS cells were infected with control shLuc,
shETS2 or miR-196b for 16 h followed by a 2 day puromycin (2 lg/ml)
selection before the cells were plated for the migration and invasion assay.
The cell migration and invasion abilities were assessed as described in the
Materials and methods. A total of 35 ﬁelds were counted for every ﬁlter. The
data are an average of triplicates for each condition.  P , 0.05,   P , 0.01.
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cer specimens. However, EMT is activated by many signaling path-
ways, such as the transforming growth factor b,W n ta n dN o t c h
pathways, in part through several intermediate critical transcription
factors, including Snail1/2, bHLH, ZEB1/2 and Twist (52). In the
in vivo three-dimensional microenvironment, EMT gene expression
might be under additional regulatory signals in addition to ETS2-
miR-196b. The investigation of downstream target genes is essential
for understanding the true biological signiﬁcance of miR-196b. MiR-
196b cannot directly target the 3#untranslated region of vimentin,
MMP2, MMP9 or E-cadherin as suggested by TargetScan predictions.
Therefore, the miR-196b promotion of AGS cell migration may be
mediated through other genes. More recently, miR-196b has been
shown to regulate several metastasis-related genes, such as Annexin
A1 and HOXB8, in various cancers (9,17,28). The detailed mechanism
of the miR-196b promotion of gastric cancer migration and invasion is
currently unclear and remains to be elucidated in future studies.
Our ﬁndings suggest that ETS2 and miR-196b play important roles
in regulating the progression of gastric tumors. The potential of ETS2
and miR-196b as novel pathological staging markers and therapeutic
targets for gastric cancer merits further investigation. The mecha-
nisms by which miRNA participates in tumor promotion and progres-
sion are diverse and complicated. Gene proﬁling studies have
demonstrated a number of signiﬁcantly deregulated miRNAs and
identiﬁed signatures of both diagnostic and prognostic value in gastric
cancer. Our report provides new insights into the regulation of onco-
genic miRNAs and their putative regulatory pathways.
Supplementary material
Supplementary Tables 1–4 and Figures 1–3 can be found at http://
carcin.oxfordjournals.org/.
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Fig. 7. Knockdown of ETS2 or overexpression of miR-196b resulted in differential expression of EMT-related genes in gastric cancer cells. (A) HR cells
expressed high levels of vimentin, MMP2 and MMP9, but AGS cells expressed high levels of E-cadherin. The expression patterns of genes were veriﬁed by RT–
qPCR. (B) The gene expression patterns of E-cadherin, vimentin, MMP2 and MMP9 were detected by RT–qPCR in shETS2-treated AGS cells and ETS2-
overexpressing HR cells. AGS cells expressed low levels of vimentin; increased expression of vimentinwas detected after ETS2 knockdown in AGS cells (western
blot). Antibodies to vimentin and actin (internal controls) were used. (C) The gene expression patterns of E-cadherin, vimentin, MMP2 and MMP9 were detected
by RT–qPCR in miR-196b-treated AGS cells and antagomir-196b-treated HR cells. (D) The gene expression patterns of E-cadherin, MMP2 and MMP9 were
detected by RT–qPCR in antagomir-196b-treated AGS–shETS2 cells. The expression levels of EMT-related genes were detected using RT–qPCR by the SYBR
Green I protocol. All values were normalized against glyceraldehyde 3-phosphate dehydrogenase mRNA. shLuc and mock were used as negative controls. The
data are an average of triplicates for each condition.  P , 0.05,   P , 0.01.
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